drugset / Trial / NCT07157033
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.
Timeline
- Start
- 2026-01-01
- Primary completion
- 2029-07-31
- Completion
- 2034-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XER-001 | Unknown | — | Other |